Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | CRHBP | P24387 | 1/20 | 0.48 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.48 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL928273 | 0.91 | MAPT (0.49) | MAPTLMNANAMPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL928845 | 0.86 | MAPT (0.45) | MAPTLMNANAMPTSMN1; SMN2 | |
| SCHEMBL926180 | 0.84 | LMNA (0.48) | MAPTLMNASMN1; SMN2ALDH1A1TP53 | |
| SCHEMBL926201 | 0.84 | MAPT (0.44) | MAPTLMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL926737 | 0.83 | LMNA (0.46) | MAPTLMNASMN1; SMN2ALDH1A1POLB | |
| SCHEMBL927527 | 0.83 | FKBP1A (0.48) | LMNASMN1; SMN2ALDH1A1POLB | |
| SCHEMBL926976 | 0.82 | HSD11B1 (0.46) | MAPTLMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL926338 | 0.82 | FKBP1A (0.49) | ALDH1A1 | |
| SCHEMBL927221 | 0.81 | EPHX2 (0.52) | MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL926562 | 0.80 | NPC1 (0.50) | LMNASMN1; SMN2ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7872021-B2 | LXR receptor modulators | LABORATORIES FOURNIER S.A. (FR) | 2011-01-18 | — | — | US | disclosed |
| US-20070099960-A1 | LXR receptor modulators | LABORATOIRES FOURNIER S.A. (FR) | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099960-A1 | LXR receptor modulators | NR1H2, NR1H3, PPARD | MAPT 1687/4885LMNA 1809/4885TSHR 271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.